Albumin conjugation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Anterior pituitary In the hypothalamic–adenohypophyseal axis, releasing hormones, also known as hypophysiotropic or hypothalamic hormones, are released from the median eminence, a prolongation of the hypothalamus, into the hypophyseal portal system, which carries them to the anterior pituitary where they exert their regulatory functions on the secretion of adenohypophyseal hormones. These hypophysiotropic hormones are stimulated by parvocellular neurosecretory cells located in the periventricular area of the hypothalamus. After their release into the capillaries of the third ventricle, the hypophysiotropic hormones travel through what is known as the hypothalamo-pituitary portal circulation. Once they reach their destination in the anterior pituitary, these hormones bind to specific receptors located on the surface of pituitary cells. Depending on which cells are activated through this binding, the pituitary will either begin secreting or stop secreting hormones into the rest of the bloodstream.
== Function == This gene encodes a precursor protein that is processed to produce oxytocin and neurophysin I. Oxytocin is a posterior pituitary hormone that is synthesized as an inactive precursor in the hypothalamus along with its carrier protein neurophysin I. Together with neurophysin, it is packaged into neurosecretory vesicles and transported axonally to the nerve endings in the neurohypophysis, where it is either stored or secreted into the bloodstream. The precursor seems to be activated while it is being transported along the axon to the posterior pituitary. This hormone contracts smooth muscle during parturition and lactation. It is also involved in cognition, tolerance, adaptation, and complex sexual and maternal behavior, as well as in the regulation of water excretion and cardiovascular functions. [provided by RefSeq, Dec 2013].
=== Agentic misalignment === "Agentic misalignment" refers to situations in which an AI agent's actions or goals diverge from its designers' intentions. This occurs when an autonomous system pursues unintended strategies to achieve its objectives, a concern studied in AI safety research. Potential examples include AI agents attempting to sabotage an organization's systems when facing updates or deactivation. On July 21, 2026, OpenAI disclosed that during a capture the flag cybersecurity test, an unreleased AI model autonomously evaded containment restrictions, gained access to the public internet, and compromised Hugging Face, a platform where developers host and share AI models and datasets. Contributing factors to the incident were a lack of log monitoring of the software activities and inadequate sandboxing. On September 24, 2026, it was announced that an internal OpenAI frontier model autonomously gained unauthorized access on June 18 to the Medicare Statistics Reporting Service, an Australian Government website that holds data on the country's universal health insurance scheme Medicare. This was described as the first known case of an AI agent hacking a government network and has furthered concern about AI safety and loss-of-control. In response to these hacks, OpenAI announced that it would slow model development, including a two-week pause on reinforcement learning of its latest models to "assess model behavior, validate our safeguards, and establish more evidence of alignment before proceeding".
Sources: en.wikipedia.org
=== WTO resources === "DS26: European Communities — Measures Concerning Meat and Meat Products (Hormones)". World Trade Organization. "DS48: European Communities — Measures Concerning Meat and Meat Products (Hormones) (Canada)". World Trade Organization. "DS320: United States — Continued Suspension of Obligations in the EC — Hormones Dispute". World Trade Organization. "DS321: Canada — Continued Suspension of Obligations in the EC — Hormones Dispute". World Trade Organization.
Raymond’s “micro-mosaics” evoked pointillism and the yet-to-come pixellation. Raymond worked with a plank of wood on his lap, a magnifying glass in one hand and a paintbrush or a dip pen in the other. He would cut the tip of the nib so he could reproduce the tesserae perfectly.
=== Ecology === Under natural conditions Brucella spp, including B. canis are obligate parasites and do not grow outside the host except in laboratory cultures. However, at specific temperatures and moisture levels Brucella can persist in soil and surface water up to 80 days. The bacterium can also survive for months in frozen conditions. B. canis is mainly found in dogs, but can also affect other wild canine species such as wolves, foxes, and coyotes. The bacterium persists in these hosts, being an adaptive pathogen towards canines. The environment these hosts reside in further contribute to the canine specificity. Dog kennels are a favored environment for the bacterium to spread due to transmission through urine and reproductive fluids. Movement of infected animals through pet trade or shelter transport also plays a critical role in the broader distribution of the bacterium. In wildlife, B. canis is also circulated through hunting and scavenging. Zoonotic transmission to humans is rare but possible, particularly for people in close contact with infected reproductive tissues. Certain occupations are at higher risk of exposure to B. canis. These persons include veterinarians, kennel workers, dog breeders, and laboratory personnel.
Sources: en.wikipedia.org
The surface tension of liquid ethylene oxide, at the interface with its own vapor, is 35.8 mJ/m2 (0.00079 cal/sq ft) at −50.1 °C (−58.2 °F) and 27.6 mJ/m2 (0.00061 cal/sq ft) at −0.1 °C (31.8 °F). The boiling point increases with the vapor pressure as follows: 57.7 °C (135.9 °F) (2 atm (200 kPa; 29 psi)), 83.6 °C (182.5 °F) (5 atm (510 kPa; 73 psi)), and 114.0 °C (237.2 °F) (10 atm (1,000 kPa; 150 psi)). Viscosity decreases with temperature with the values of 0.577 kPa·s at −49.8 °C (−57.6 °F), 0.488 kPa·s at −38.2 °C (−36.8 °F), 0.394 kPa·s at −21.0 °C (−5.8 °F), and 0.320 kPa·s at 0 °C (32 °F). Between −91 and 10.5 °C (−131.8 and 50.9 °F), vapor pressure p (in mmHg) varies with temperature (T in °C) as
1961), author of Penguin Books Users: How Big Tech Took Control and How to Fight Back; filmmaker, politician and social activist; advocate for children's rights in the digital world; establishing standards for online safety and privacy across the world; sits as a crossbench peer in the United Kingdom's House of Lords; she is an advisor to the Institute for Ethics of artificial intelligence at Oxford University, a commissioner on the Broadband Commission for Sustainable Development, and founder of 5Rights Foundation; sister of record producer Adam Kidron; daughter of British Israeli of South African origin, Michael Kidron, founder of leftist Pluto Press; niece of Socialist Workers Party founder Tony Cliff and activist Chanie Rosenberg, and the cousin of historian Donny Gluckstein.; appointed Officer of the Order of the British Empire (OBE) in the 2012 Birthday Honours for services to drama. Sophia King (later Fortnum; b. 1781/2, d. in or after 1805) Gothic novelist and poet, and sister of Gothic writer Charlotte Dacre. She contributed to poetry periodicals under the nom-de-plume "Sappho".
== National differences and how to specialise == Australia In Australia, transfusion medicine is a sub-specialty of haematology. Training in transfusion medicine is covered by the Royal College of Pathologists of Australasia (RCPA). Australia has national blood services operated by the Australian Red Cross Blood Service. There are a series of guidelines and standards relevant to the laboratory released by the National Association of Testing Authorities, Australia (NATA), Australian and New Zealand Society of Blood Transfusion (ANZSBT) and RCPA. Similarly, there are a series of clinical practice, patient blood management guidelines by the National Blood Authority. In Australia, the Serious Transfusion Incident Reporting (STIR) system is in place to capture serious transfusion incidents and near-miss incidents.
== History == Dextromoramide was discovered and patented in 1956 by Paul Janssen at Janssen Pharmaceuticals, who also discovered fentanyl, another important synthetic opioid, widely used to treat pain and in combination with other drugs as an anaesthetic, as well as haloperidol, piritramide, the loperamide-diphenoxylate series and other important drugs. Dextromoramide was much favoured by drug users in Australia in the 1970s and the United Kingdom. It has the main proprietary name of Palfium amongst others, though as of mid-2004 the drug was discontinued in the UK due to limited supplies of precursor chemicals. Although this is true, it is believed there was an approximate one year shortage of Dextromoramide and the real reason that Palfium was not put back into production for the UK market is because of how addictive and potent it is as an oral painkiller. Dependence liability is similar to morphine, but with a less severe withdrawal syndrome. The only European countries that now use the brand Palfium are the Netherlands, Ireland and Luxembourg. It is presumably able to be imported into other Schengen zone countries under Title 76 of said treaty coming into force in 2002. It is a Schedule I Narcotic controlled substance in the United States, with a DEA ACSCN of 9613 and an annual aggregate manufacturing quota of zero as of 2013, and had been out of use in the United States for around a decade when the new Controlled Substances Act 1970 was promulgated. The salts of dextromoramide in use are the hydrochloride (free base conversion ratio 0.915) and tartrate (0.724).
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.